Pay in 4 interest-free payments of $6.82 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
WEDNESDAY, July 23, 2025 (HealthDay News) -- Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with reduced type 2 diabetes mellitus (T2DM)-related dementia risk compared with metformin, according to a study published online July 22 in BMJ Open Diabetes Research & Care.Mingyang Sun, from the People's Hospital of Zhengzhou University in China, and colleagues conducted a retrospective cohort study using data from a global health research network between 2004 and 2024 to examine the comparative effectiveness of GLP-1 RAs and metformin in reducing dementia risk
Depression or suicidal thoughts: Any noticeable changes in mood, behavior, or thoughtsespecially those that feel intense or unusualshould be shared with a healthcare provider right away
1% on placebo) The crucial detail that gets lost in these numbers: most of these side effects are transient
z , AUC of y
US$ 29.72
US$ 27.33
US$ 22.66
US$ 22.61
US$ 28.58
